John L. Berk, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Case Western Reserve University



Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.


Expanded Access Protocol of Patisiran for Patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polynenropathy
10/31/2016 - 10/30/2021 (PI)
Alnylam Pharmaceuticals, Inc.


A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlle Study to Evaluate the Efficacy and Safety of ALN-TTRSC in Patients with Transthyretin Mediated Familial Amyloidotic
07/28/2015 - 07/28/2020 (PI)
Alnylam Pharmaceuticals, Inc.


A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETI
04/04/2017 - 04/03/2020 (PI)
Pfizer, Inc.


Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study with
03/29/2016 - 03/28/2019 (PI)
Alnylam Pharmaceuticals, Inc.


Treatment Use of Eprodisate (Klacta) In a Patient Diagnosed with AA Amyloidosis
02/16/2016 - 02/15/2019 (PI)
A.T. Development Switzerland Sarl


A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826)
10/17/2014 - 05/31/2018 (PI)
Pfizer, Inc.


BU-Alnylam Diflunisal Research Collaboration
10/01/2015 - 10/15/2017 (PI)
Alnylam Pharmaceuticals, Inc.


APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy
07/01/2014 - 09/30/2017 (PI)
Alnylam Pharmaceuticals, Inc.


An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
09/30/2014 - 09/29/2017 (PI)
Ionis Pharmaceuticals, Inc.


A phase 2, open-label, multi-dose, dose escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous infusions of ALN-TTR02 in patients with TTR Amyloid
08/27/2013 - 08/31/2017 (PI)
Alnylam Pharmaceuticals, Inc.


Showing 10 of 17 results. Show All Results



Yr Title Project-Sub Proj Pubs
2009 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-05 9
2008 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-04 9
2007 THE EFFECT OF DIFLUNISAL ON HEREDITARY AMYLOIDOSIS 2M01RR000533-39-8163 429
2007 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-03 9
2007 Effect of diflunisal on familial amyloidosis 5R01FD002532-03 2
2006 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-02 9
2006 Effect of diflunisal on familial amyloidosis 5R01FD002532-02 2
2005 Effect of diflunisal (IND68092) on familial amyloidosis 1R01NS051306-01 9
2001 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-33-353 429
2000 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-32-353 429
Showing 10 of 15 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Mar 08; 1-2.View Related Profiles. PMID: 29516761.
     
  2. Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar; 25(1):62-67.View Related Profiles. PMID: 29424556.
     
  3. Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018 Feb; 11(2):e004000.View Related Profiles. PMID: 29449366.
     
  4. Arvanitis M, Chan GG, Jacobson DR, Berk JL, Connors LH, Ruberg FL. Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. Amyloid. 2017 Dec; 24(4):253-255.View Related Profiles. PMID: 29052438.
     
  5. Schonhoft JD, Monteiro C, Plate L, Eisele YS, Kelly JM, Boland D, Parker CG, Cravatt BF, Teruya S, Helmke S, Maurer M, Berk J, Sekijima Y, Novais M, Coelho T, Powers ET, Kelly JW. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. 2017 Sep 13; 9(407). PMID: 28904227.
     
  6. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017 Sep 01; 18(9):1057-1064.View Related Profiles. PMID: 27965280; DOI: 10.1093/ehjci/jew298;.
     
  7. Berk JL. Artificial neural network modelling of ATTR amyloidosis: is now the time? Amyloid. 2017 Sep; 24(3):141-142. PMID: 28719235.
     
  8. Govender P, Keyes CM, Hankinson EA, O''Hara CJ, Sanchorawala V, Berk JL. Transbronchial biopsies safely diagnose amyloid lung disease. Amyloid. 2017 Mar; 24(1):37-41.View Related Profiles. PMID: 28393574; DOI: 10.1080/13506129.2017.1301917;.
     
  9. Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceição I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ. Assessing mNIS+7Ionis and international neurologists'' proficiency in a familial amyloidotic polyneuropathy trial. Muscle Nerve. 2017 Nov; 56(5):901-911.View Related Profiles. PMID: 28063170; DOI: 10.1002/mus.25563;.
     
  10. Pulido V, Doros G, Berk JL, Sanchorawala V. The six-minute walk test in patients with AL amyloidosis: a single centre case series. Br J Haematol. 2017 May; 177(3):388-394.View Related Profiles. PMID: 28340285; DOI: 10.1111/bjh.14586;.
     
Showing 10 of 76 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 76 publications over 23 distinct years, with a maximum of 10 publications in 2017

YearPublications
19871
19911
19931
19942
19962
19983
19993
20002
20012
20023
20032
20043
20054
20071
20101
20117
20125
20135
20144
20157
20164
201710
20183
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloid lung disease
amyloidosis
familial amyloidotic polyneuropathy
pleural effusions
pulmonary fibrosis
tracheobronchial amyloidosis
Contact for Mentoring:


72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Berk's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department